{"input_url":"https://insilico.com/news/isn1009261-insilico-medicine-doses-first-patient-genesis-ipf-3","gnews_decode":"https://insilico.com/news/isn1009261-insilico-medicine-doses-first-patient-genesis-ipf-3","http_status":200,"final_url":"https://insilico.com/news/isn1009261-insilico-medicine-doses-first-patient-genesis-ipf-3","html_length":45877,"trafilatura_result":"ok","text_length":8418,"text_preview":"CAMBRIDGE, Mass., Sep 10, 2026 — Insilico Medicine (“Insilico,” HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687","verdict":"OK"}